![]() ![]() Novartis developed the IV formulation of Cosentyx in response to the need for additional choices for patients who may not be comfortable with subcutaneous self-injection, prefer in-office administration by their healthcare provider, or might be interested in a different mechanism of action than other biologic IV therapies for these conditions that does not include a boxed warning or require pre-medication or lab monitoring. “We’re working closely with healthcare systems and payers to establish medical policies and coverage, based on the clinical value and patient benefit that Cosentyx offers,” the spokesperson said.Įligible patients with commercial insurance could pay as little as $0 out of pocket through the Novartis copay assistance program. The IV formulation has a wholesale acquisition cost of $2,115 per vial, which a company spokesperson said is priced in line with other IV biologics in its class. The list price for the injection formulation is $6,924.26 for a month’s supply. Cosentyx, which targets and blocks interleukin-17A (IL-17A), is also available as a self-injection. The IV formulation of Cosentyx is a monthly 30-minute, weight-based dosing option. The new IV administration option will be available in the fourth quarter of 2023. The FDA has approved an intravenous (IV) form of Novartis’ Cosentyx (secukinumab) to treat adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |